Can CBD tame seizures in severe childhood epilepsy? a major trial aims to find out
NCT ID NCT07723976
First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether a cannabidiol oral solution (CBD-OS) can safely reduce seizures in people aged 1 year and older with developmental and epileptic encephalopathy (DEE), a group of severe epilepsy syndromes. Participants receive either CBD or a placebo twice daily for several weeks. The study measures changes in seizure frequency and caregiver-reported improvements.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cannabidiol oral solution (CBD-OS, JZP926-OS)
- What this could lead to
- If effective, this could provide a new treatment option to reduce seizures in people with developmental and epileptic encephalopathy.
- What could go wrong
- This is a phase 3 trial, but results may not apply to all DEE types. Side effects of CBD can include drowsiness, diarrhea, and liver enzyme changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEVELOPMENTAL AND EPILEPTIC ENCEPHALOPATHY (DEE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••